OLE

DIETARY_SUPPLEMENT2 trials

Sponsors

Forma Therapeutics, Inc., Société des Produits Nestlé (SPN)

Conditions

Healthy SubjectsSickle Cell Disease SCD

Phase 3

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease

RecruitingLBCTR2021124934

Forma Therapeutics, Inc.Sickle Cell Disease SCD

Start: 2022-03-07Target: 344Updated: 2026-02-02

Unknown Phase

Effects of Enzymatic Digestion and Probiotic on Oleuropein Bioavailability

CompletedNCT04328571

Société des Produits Nestlé (SPN)Healthy Subjects

Start: 2020-02-10End: 2021-09-15Updated: 2021-10-01